학술논문

10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
Document Type
Article
Author
Lübbert, MichaelWijermans, Pierre WKicinski, MichalChantepie, SylvainVan der Velden, Walter J F MNoppeney, RichardGriškevičius, LaimonasNeubauer, AndreasCrysandt, MartinaVrhovac, RadovanLuppi, MarioFuhrmann, StephanAudisio, ErnestaCandoni, AnnaLegrand, OlivierFoà, RobinGaidano, Gianlucavan Lammeren-Venema, DaniellePosthuma, Eduardus F MHoogendoorn, MelsGiraut, AnneStevens-Kroef, MarianJansen, Joop Hde Graaf, Aniek OEfficace, FabioAmmatuna, EmanueleVilque, Jean-PierreWäsch, RalphBecker, HeikoBlijlevens, NicoleDührsen, UlrichBaron, FrédéricSuciu, StefanAmadori, SergioVenditti, AdrianoHuls, GerwinFinke, JürgenSchaap, Nicolaas Petrus MichaelZucenka, AndriusMetzelder, StephanJost, EdgarPerić, ZinaidaForghieri, FabioAllione, BernadinoMartelli, MaurizioIori, Anna PaolaWittnebel, SebastianMengarelli, AndreaImovilli, AnnalisaOlivieri, AttilioDe Prijck, Bernard José Marievan der Poel, Marjolein W.M.Junghanß, ChristianSalih, Helmut RainerTafuri, AgostinoGuimarães, José EduardoMusso, MaurizioDe Fabritiis, PaoloChevallier, PatriceSelleslag, Dominik LucCascavilla, NicolaBerneman, ZwiJaspers, AurélieZuffa, ElianaVanstraelen, GaëtanVisani, GiuseppeCuijpers, Maria Louisa HenriëtteDe Becker, AnnMianulli, Anna MariaHackanson, BjörnMihaylov, Georgi GeorgievMartinelli, GiovanniPaolini, StefaniaZinzani, Pier LuigiHenkes, MartinAl-Ali, Haifa KathrinLa Rosée, PaulChierichini, AnnaCudillo, LauraSpecchia, GiorginaŠimec, Njetočka GredeljCapalbo, Silvana FrancaSpinosa, GiuseppinaMolica, Stefanode Jonge-Peeters, Susan Dorothé
Source
The Lancet Haematology; November 2023, Vol. 10 Issue: 11 pe879-e889, 11p
Subject
Language
ISSN
23523026
Abstract
Many older patients with acute myeloid leukaemia die or cannot undergo allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by intensive chemotherapy. We hypothesised that replacing intensive chemotherapy with decitabine monotherapy could improve outcomes.